Rekrutuje
Badanie kliniczne
Videolaryngoscopes in the Morbidly Obese
W Polsce: RekrutujeNa świecie: Rekrutuje
Otyłość: badanie kliniczne
Tytuł w rejestrze: Better4All Personalized Intervention Pilot Study
Najważniejsze informacje
- Choroba
- Otyłość (Obesity Prevention)
- Status w Polsce
- Rekrutujestany polskich ośrodków według ClinicalTrials.gov
- Status na świecie
- Rekrutujestan całego badania w rejestrze
- Wiek uczestników
- 18-65 lat
- Płeć
- kobiety i mężczyźni
- Zdrowi ochotnicy
- tak
- Planowana liczba uczestników
- łącznie 490
- Sponsor
- Harokopio University
- Terminy (planowane)
- 1 czerwca 2025 - 30 września 2025
- Kraje
- 7: Cypr, Francja, Grecja, Hiszpania, Polska, Portugalia, Szwecja
- Numer w rejestrze
- NCT07120802 (ClinicalTrials.gov)
Gdzie prowadzone jest badanie
Ośrodki prowadzące badanie w Polsce (1), alfabetycznie według miejscowości:
- Uniwersytet Swps (Swps) RekrutujeWrocławKontakt
rekrutuje wkrótce nie rekrutuje lub brak danych
Kliknij kropkę, żeby zobaczyć ośrodki w mieście.
Więcej badań w tych miastach:
Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.
Cel badania
Opis z rejestru (w języku angielskim):
The BETTER4U project (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you) is funded by the European Union (EU) and involves an international consortium consisting of 28 partners across Europe, Israel, and Australia. The project started in November 2023 and will run until October 2027. The main aim of BETTER4U is to improve weight management through a tailor-made intervention, the "BETTER4ALL personalized intervention", using modern monitoring tools and artificial intelligence (AI), including machine learning (ML) practices.
In the context of the BETTER4U project, the present Pilot Study aims to a) evaluate the usability, feasibility and acceptability of the BETTER4U mobile application ("BETTER4U App") and Intervention Platform that will be used to monitor and collect data from participants in the BETTER4ALL personalized intervention (randomized controlled trial; RCT) and b) collect data to evaluate and improve the BETTER4U causal AI models for the prevention of weight gain, before deploying them at large scale, as well as test and identify the optimal ways of delivering the AI-based interventions to the participants. The study will be conducted in seven sites in Cyprus, France, Greece, Poland, Portugal, Spain, and Sweden.
The BETTER4All Pilot Study will be a longitudinal, correlational, observational study, including a total of n=490 participants, equally distributed among the seven sites (i.e. n=70 per site). Specifically, n=60 (± 3-5) "general population" participants (henceforth: "end-users" of the wearables and the BETTER4U App) and n=10 (± 3-5) healthcare or other types of providers (henceforth: potential "implementers" of the BETTER4U intervention) will constitute each site's sample.
The study will involve the following two components: a) the administration of the wearables (smartwatches) to the "end-users" and their registration to and training on the BETTER4U App, to be used for a total duration of three weeks (21 days). During this period, their lifestyle behaviours (i.e. "BETTER4U Core Behavioural Indicators - BCBIs", such as eating occasions, physical activity, sedentary time, sleep etc.) and "living environment indicators - LEIs"; (e.g. access to parks in your area, distance from your home to your work place etc.) will be recorded daily, either in an automated way via the wearables or self-reported by the end-users through the App; and b) the registration to and training on the BETTER4U Intervention Platform of the "implementers" for a total duration of one week (7 days), during which they will be asked to test the platform's functionalities using synthetic data. The implementers will also be provided with the wearables and the App (similarly to the end-users) for one week only to allow collection of additional data that will help verify the accuracy of the algorithms in the gathered data from the wearables/monitoring tools regarding BCBIs and LEIs.
Overall, the outcomes and the findings of the Pilot Study will be used to further refine, optimize, and adjust the tools for the BETTER4ALL RCT, according to the feedback received by both end-users' and implementers' perspectives.
Leczenie w badaniu
| Lek / interwencja | Rola | Postać, podanie |
|---|---|---|
| BETTER4U Mobile App and Wearable Use (End-User Group) | Interwencja behawioralna | |
| BETTER4U Intervention Platform Testing (Implementer Group) | Interwencja behawioralna |
Kryteria udziału
Kryteria w języku angielskim, tak jak w rejestrze.
Kryteria włączenia kto może wziąć udział (12)
- Age: Participants aged 18-65 years to represent the adult general population.
- Body Mass Index (BMI):
- Overweight or obesity group: BMI ≥ 25 kg/m².
- Normal weight group: BMI 18.5-24.9 kg/m².
- Technology Use:
- Willingness and ability to use wearable devices and an Android mobile application for the duration of the study.
- Owning a smartphone device with the Android operating system.
- Eating utensil technique: dominant hand gestures that correspond to handling of food via a fork or a spoon.
- Language Proficiency: Ability to read and understand the language in which the mobile app and study materials are provided.
- Consent: Willing to provide informed consent to participate in the study.
- Residency: Must be a resident of one of the seven participating countries.
- Availability: Able to participate for the full three-week duration of the study and comply with the study protocol.
Kryteria wyłączenia kto nie może wziąć udziału (4)
- Health Conditions: Pregnant or breastfeeding women, as they might have different lifestyle behaviours or health needs.
- Physical Limitations: Any physical or mental condition that would prevent the participant from using the wearable device or mobile application as intended.
- Eating utensil technique: eating food with chopsticks on a daily or regular basis.
- Technical Incompatibility: Individuals who do not own a compatible smartphone or are unable to use the provided wearable devices for technical reasons.
To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.
Zapytaj o udział w tym badaniu
Zadzwoń, a nasz doradca ds. badań sprawdzi z Tobą wstępnie kryteria i pomoże skontaktować się z ośrodkiem. Kwalifikację zawsze przeprowadza lekarz w ośrodku. Udział w badaniu jest bezpłatny i dobrowolny.
Zadzwoń do naszego specjalisty+48 664 930 800pon-pt: 9:00 - 18:00
Wolisz, żebyśmy oddzwonili? Zostaw numer
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Inne badania: otyłość
RekrutujeFaza III
Cukrzyca: badanie fazy III leku AZD6234
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Badane leki: AZD6234
+8
+8RekrutujeFaza III
Cukrzyca: badanie fazy III leku AZD6234
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Badane leki: AZD6234
+8
+8RekrutujeFaza III
Badanie fazy III leku semaglutide
Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity
Badane leki: semaglutide
+2
+2RekrutujeFaza III
Badanie fazy III leku ASC30
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Badane leki: ASC30
RekrutujeFaza III
Cukrzyca: badanie fazy III leku ASC30
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Badane leki: ASC30
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.